Transjugulärer intrahepatischer portosystemischer Shunt (TIPS) – Update 2016

Inge Kaare Tesdal

doi:10.1055/s-0042-117560

Gastroenterologie up2date, Table of Contents

Gastroenterologie up2date 2016; 12(04): 321-339
DOI: 10.1055/s-0042-117560

Leber/Galle/Pankreas

Transjugulärer intrahepatischer portosystemischer Shunt (TIPS) – Update 2016

Inge Kaare Tesdal

Abstract

All articles of this category

Full Text

References

Literatur
1 Tesdal IK. Transjugulärer intrahepatischer portosystemischer Shunt (TIPS): Indikation, Durchführung, Komplikationen. Gastoenterologie up2date 2007; 3: 359-373
2 Hanafee W, Weiner M. Transjugular percutaneous cholangiography. Radiology 1967; 88: 35-39
3 Weiner M, Hanafee W. Review of transjugular venography. Radiol Clin North Am 1970; 8: 53-68
4 Rösch J, Hanafee WN, Snow H. Transjugular portal venography and radiologic portacaval shunt: an experimental study. Radiology 1969; 92: 1112-1114
5 Colapinto RF, Stronell RD, Birch SJ et al. Creation of an intrahepatic portosystemic shunt with Grüntzig balloon catheter. Can Med Assoc J 1982; 113: 137-138
6 Palmaz JC, Sibbitt RR, Reuter SR et al. Expandable intrahepatic portacaval shunt stents: early experience in the dog. AJR Am J Roentgenol 1985; 145: 821-825
7 Rössle M, Richter GM, Nöldge G et al. Performance of an intrahepatic portacaval shunt (PCS) using a catheter technique: A case report. Hepatology 1988; 8: 1348A
8 Lunderquist A, Vang J. Transhepatic catheterization and obliteration of the coronary vein in patients with portal hypertension and esophageal varices. N Engl J Med 1974; 291: 646-649
9 Mitra SK. Hepatic vascular changes in human and experimental cirrhosis. J Pathol Bacteriol 1966; 92: 405-414
10 Bosch J, Navasa M, Garcia-Pagan JC et al. Portal hypertension. Med Clin North Am 1989; 73: 931-953
11 Christensen E, Faverholdt L, Schlichting P et al. Aspects of the natural history of gatrointestinal bleeding in cirrhosis and the effect of prednisone. Gastroenterology 1981; 81: 944-952
12 The Veterans Affairs Cooperative Variceal Sclerotherapy Group. Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. N Engl J Med; 1991 324. 1779-1784
13 The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med; 1988 319. 983-989
14 Burroughs AK. The natural history of varices. J Hepatol 1993; 17: 10-13
15 Olafsson S, Blei AT. Diagnosis and management of ascites in the age of TIPS. AJR Am J Roentgenol 1995; 165: 9-15
16 Shiffman ML, Jeffers L, Hoofnagle JH et al. The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: A conference sponsored by the national digestive diseases advisory board. Hepatology 1995; 22: 131-137
17 Haskal ZJ, Martin L, Cardella JF et al. Quality improvement guidelines for transjugular intrahepatic portosystemic shunts. SCVIR Standards of Practice Committee. J Vasc Interv Radiol 2001; 12: 131-136
18 Boyer TD, Haskal ZJ The role of transjugular intrahepatic portosystemic shunt in the American Association for the Study of Liver Diseases.management of portal hypertension: update 2009. Hepatology; 2010 51. 306
19 García-Pagán JC, Caca K, Bureau C et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362: 2370-2379
20 Henderson JM. Surgery versus transjugular intrahepatic portal systemic shunt in the treatment of severe variceal bleeding. Clin Liver Dis 2006; 10: 599-612
21 Tesdal IK, Wikström M, Flechtenmacher C et al. Percutaneous treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol 2006; 29: 778-784
22 Qi X, Han G. TIPS in the treatment of portal vein thrombosis: a critical review of literature. Hepatol Int 2012; 6: 576-590
23 Malinchoc M, Kamath PS, Gordon FD et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-871
24 Angermayr B, Cejna M, Karnel F et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 2003; 52: 879-885
25 Burroughs AK, Vangeli M. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis. Scand J Gastroenterol 2002; 3: 249-252
26 Sauerbruch T, Mengel M, Dollinger M et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology 2015; 149: 660-668
27 Angermayr B, Cejna M, Koenig F et al. for the Vienna TIPS Study Group. Survival in patients undergoing TIPS: ePTFE-covered stent grafts versus bare stents. Hepatology 2003; 38: 1043-1050
28 Carbonell N, Pauwels A, Serfaty L et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004; 40: 652-659
29 Rössle M, Haag K, Ochs A et al. The transjugular intrahepatic portosystemic shunt. N Engl J Med 1994; 330: 165-171
30 Sahagun G, Benner KG, Saxon R et al. Outcome of 100 patients after transjugular intrahepatic portosystemic shunt for variceal hemorrhage. Am J Gastroenterol 1997; 9: 1444-1452
31 Sanyal AJ, Freedman AM, Luketic VA et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997; 112: 889-898
32 Borg J PC, Hollemans M, Henk B RV et al. Transjugular intrahepatic portosystemic shunts: long-term patency and clinical results in a patient cohort observed for 3–9 years. Radiology 2004; 231: 537-545
33 Tesdal IK, Filser T, Weiss C et al. Transjugular intrahepatic portosystemic shunts: adjunctive embolotherapy of gastroesophageal collateral vessels in the prevention of variceal rebleeding. Radiology 2005; 236: 360-367
34 Gaba RC, Bui JT, Cotler SJ et al. Rebleeding rates following TIPS for variceal hemorrhage in the Viatorr era: TIPS versus TIPS with variceal embolization. Hepatol Int 2010; 4: 749-756
35 Qi X, Liu L, Bai M et al. Transjugular intrahepatic portosystemic shunt in combination with or without variceal embolization for the prevention of variceal rebleeding: a meta-analysis. J Gastroenterol Hepatol 2014; 29: 688-696
36 Russo MW, Sood A, Jacobson IM et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. Am J Gastroenterol 2003; 98: 2521-2527
37 Lebrec D, Giuily N, Hadengue A et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol 1996; 25: 135-144
38 Rössle M, Ochs A, Gulberg V et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701-1707
39 Gines P, Uriz J, Calaborra B et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 1839-1847
40 Sanyal A, Genning C, Reddy KR et al. The North American study for the treatment of refractory ascites. Gastroenterology 2003; 124: 634-641
41 Salerno F, Merli M, Riggio O et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40: 629-635
42 Narahara Y, Kanazawa H, Fukuda T et al. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol 2011; 46: 78-85
43 Rössle M, Olschewski M, Siegerstetter V et al. The Budd-Chiari syndrome: outcome after treatment with transjugular intrahepatic portosystemic shunt. Surgery 2004; 135: 394-403
44 Darwish MS, Valla DC, de Groen PC et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004; 39: 500-508
45 Garcia-Pagán JC, Heydtmann M, Raffa S et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology 2008; 135: 808-815
46 Neumann AB, Andersen SD, Nielsen DT et al. Treatment of Budd-Chiari syndrome with a focus on transjugular intrahepatic portosystemic shunt. World J Hepatol 2013; 5: 38-42
47 Darwish MS, Luong TK, Pattynama PM et al. Long-term outcome of a covered vs. uncovered TIPS-Shunt in Budd-Chiari syndrome. Liver Int 2008; 28: 249-256
48 Seijo S, Plessier A, Hoekstra J et al. Good long-term outcome of budd-chiari syndrome with a step-wise management. Hepatology 2013; 57: 1962-1968
49 Darwish MS, Kamath PS. Liver transplantation for Budd-Chiari syndrome: when is it really necessary?. Liver Transpl 2008; 14: 133-135
50 Senzolo M, Tibbals J, Cholongitas E et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther 2006; 23: 767-775
51 Qi X, He C, Guo W et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with variceal bleeding in liver cirrhosis: outcomes and predictors in a prospective cohort study. Liver Int 2016; 36: 667-676
52 Tesdal IK, Jaschke W, Bühler M et al. Transjugular intrahepatic portosystemic shunting (TIPS) with balloon-expandable and self-expanding stents: technical and clinical aspects after 31/2 years experience. Cardiovasc Interv Radiol 1997; 20: 29-37
53 Bureau C, Garcia-Pagan JC, Otal P et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004; 126: 469-475
54 Wilhelm K, Textor J, Strunk H et al. Kohlendioxid (CO2)als Kontrastmittel zur Neuauflage und Kontrolle von TIPS. Rofo 1997; 166: 238-242
55 Coldwell DM, Ring EJ, Rees CR et al. Multicenter investigation of the role of transjugular intrahepatic portosystemic shunt in management of portal hypertension. Radiology 1995; 196: 335-340
56 Shiffman ML, Cole PE. Complications of TIPS implantation. In: Conn HO, Palmaz JC, Rösch J, Rössle M, , eds. Transjugular intrahepatic portosystemic shunts. New York: Igaku-Shoin; 1996
57 Davis AG, Haskal ZJ. Extrahepatic portal vein puncture and intra-abdominal hemorrhage during transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol 1996; 7: 863-866
58 Rössle M, Haag K, Blum HE. The transjugular intrahepatic portosystemic stent-shunt: a review of the literature and own experiences. J Gastroenterol Hepatol 1996; 11: 293-298
59 Grosso M, Spalluto F, Muratore P et al. Palmaz stent dislodgement into the left pulmonary artery complicating TIPS: percutaneous retrieval and extraction after venotomy. Cardiovasc Intervent Radiol 1995; 18: 106-108
60 Córdoba J, López-Hellín J, Planas M et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004; 41: 38-43
61 Brunner F, Dufour JF, Gottardi AD. Therapie und Prävention der hepatischen Enzephalopathie. Schweiz Med Forum 2014; 14: 523-525
62 Sidhu SS, Goyal O, Mishra BP et al. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011; 106: 307-316
63 Bajaj JS, Heuman DM, Wade JB et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011; 140: 478-487
64 Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol 2001; 96: 1968-1976
65 Zhan T, Stremmel W. Diagnostik und Therapie der minimalen hepatischen Enzephalopathie. Dtsch Arztebl Int 2012; 109: 180-187
66 Wu D, Wu SM, Lu J et al. Rifaximin versus nonabsorbable disaccharides for the treatment of hepatic encephalopathy: a meta-analysis. Gastroenterol Res Pract 2013; 2013: 236963
67 Jiang Q, Jiang XH, Zheng MH et al. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2008; 20: 1064-1070
68 Sharma P, Sharma BC, Agrawal A et al. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 2012; 27: 1329-1335
69 Pereira K, Carrion AF, Salsamendi J et al. Endovascular management of refractory hepatic encephalopathy complication of TIPS: comprehensive review and clinical practice algorithm. Cardiovasc Intervent Radiol 2016; 39: 170-182